• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

• 페이스북 공유
• 트위터 공유

Stem cells show promising results for treating youngsters with neurological diseases corresponding to CP and AST.

Stem cells and cerebral palsy, CP:

CP is an abbreviation of the Latin identify Cerebral Palsy. Palsy which means weakness or problems with using the muscles. Cerebral that means, having to do with the brain. CP is brought on by abnormal mind growth or injury to the developing mind that seem in early childhood and affects a person´s potential to regulate his or her muscles permanently. Worldwide, the frequency is 2-3 cases/a thousand dwell births 1. Of the roughly a hundred 000 youngsters born in Sweden yearly simply over 200 are affected by CP. Behavioural problems are also widespread in youngsters with CP, including neuropsychiatric disorders corresponding to ADHD (attention deficit hyperactivity disorder) and autism spectrum disorders (ASD). There is no known cure for CP, however supportive remedies, medications, and surgery might help many individuals to reduce signs and disabilities while additionally improving mobility. This may include i.e. bodily therapy and speech therapy.

Joanne Kurtzberg is one of the crucial distinguished researchers performing clinical trials with umbilical cord blood stem cells for the treatment of diseases and syndromes that have an effect on the central nervous system2.

In 2010, Dr Kurtzberg performed her first trial on the security and feasibility of cord blood to treat acquired neurological disorders like cerebral palsy 3. Subsequent randomized, double-blind, placebo-managed section II research by Dr. Kurtzberg examined the impact of a single dose of autologous umbilical cord blood. The study from 2017 followed sixty three children between ages of one and 6 years who had cerebral palsy due to brain harm occurred before or in reference to start, had similar optimistic study results 4. The members had been given a spread of doses, from 10 million cells to 50 million cells per kg of body weight.

One yr after therapy, all contributors who received umbilical cord blood showed improvement in motor function and mind activity.

Children who obtained a higher dose of umbilical cord blood of a minimum of 25 million cells per kg of physique weight, confirmed larger enhancements compared to youngsters treated with a lower dose or placebo. This result's supported by two different randomized clinical trials within cell therapy, the place they evaluated the use of cord blood stem cell infusion for the therapy of cerebral palsy in children 5,6.

Here you can find registered clinical trials with umbilical cord blood for the remedy of CP harm, which recruits:

https://parentsguidecordblood.org/en/trials/cerebral-palsy

If you'd like extra info about a clinical trial click on the link for the registration quantity for the clinical trial you might be all for and you will get the registration for it on the clinical trial webpage: https://clinicaltrials.gov/

Contact information will be present in the description for the clinical trial.

Today it is not known which stem cells could be higher for treating patients with neurological situations comparable to autism and CP-harm, umbilical cord blood or mesenchymal stem cells, MSC from the umbilical cord.

In a research from 2021, by Amanat, et al., the impact of umbilical cord MSC was evaluated as a therapy for kids with CP. The study included seventy two kids aged 4-14 years, with CP skada7. Half of the participants received one dose of MSC from cord tissue, and the other half obtained placebo treatment. All patients commonly participated in rehabilitation therapy during the clinical trial. To evaluate the therapy impact of the stem cells, several analysis devices have been used that measure neurological symptoms, varied bodily capabilities, and different functional abilities. Significant modifications could be seen six months after treatment, when patients who obtained stem cells began to point out important enhancements in motor operate.

The youngsters confirmed an elevated ability for self-care and had been better capable of work together with associates and family and participated in numerous activities.

To evaluate the impact of the treatment, a change within the white matter of the mind was additionally measured, with Diffusion Tensor Imaging, DTI earlier than and after treatment. DTI is a know-how that may visualize nerve pathways and, for instance, adjustments in the white matter in the brain. Data from DTI showed vital enhancements within the structural integrity of the white matter of the brain for the patients handled with stem cells.

Stem cells and autism spectrum disorder (ASD):

Autism Spectrum Disorder (ASD) are a gaggle of developmental disabilities that may cause vital social, communication and behavioural challenges. CP is the result of mind harm that happens earlier than, throughout or shortly after start whereas the ethiology and pathogenesis of ASD are largely unknown though it is extensively accepted that environmental, epigenetic, https://autismtreatmentcare.com/ and inflammatory components all contribute to the development of Ads. There are no medications that can cure ASD or treat the core signs. However, there are medications that may also help some individuals with ASD perform better.

Recent studies show that stem cell therapy might effectively cure CP. These advances have inspired the usage of stem cell therapy in ASD (which is far more widespread).

The proof base is growing that remedy with autologous stem cells from the umbilical cord blood can considerably improve function of youngsters with CP and other neurological diseases reminiscent of i.e. ASD writes Boruczkowski, et al., in a overview revealed in 20198. The article is predicated on publications from PubMed and clinical trials registered at ClinicalTrials.gov and the aim is to compile current data and clinical use of umbilical cord blood. Several clinical research also verify the safety and efficacy of the usage of umbilical cord blood (autologous and in addition allogeneic), including a meta-evaluation of 5 clinical trials 9.

In early 2017, Duke University launched the results from a section I research on the safety of treating youngsters with autism with a single intravenous infusion of their own umbilical cord blood10 .

The researchers discovered that amongst 25 kids ages 2-5, greater than two-thirds appeared to point out improvements in speech, socialization, and eye contact. The trial included two evaluations: one at six months and another at 12 months. On the six-month evaluations, between 60 and 70 % of the kids confirmed enhancements in points of their autism together with sensory behaviours, receptive and expressive communication, and social withdrawal.

In one examine by Dawson, et al.,11 180 youngsters aged 2-7 years have been randomized to treatment with umbilical cord blood or placebo and had been evaluated 6 months submit infusion.

There was no difference in improvement of social communication or AST symptoms between therapy and placebo groups. However, the sub-group of kids without mental incapacity who have been treated with cord blood demonstrated important improved communication, increased sustained attention in eye tracking assessments, and increase in alpha and beta energy on EEG compared to placebo.

Duke University recently opened a part II randomized, placebo managed, clinical trial, NCT04089579, testing cord tissue mesenchymal stem cells (MSCs) to treat AST. It should enrol 164 kids ages 4-8 years. Estimated Primary Completion Date of the research is October 2022.

Expanded Access Program for the remedy of CP and other neurological diseases:

The term EAP comes from the FDA in the United States, the place it is used to describe a program that allows patients with a severe sickness or situation to have access to a trial drug that has been shown to be safe the place the effect continues to be being studied and the place there is no such thing as a comparable or satisfactory alternative treatment.

The primary expanded access program (EAP) of cord blood stem cell therapy for CP and other neurological diseases was launched in 2017:

https://parentsguidecordblood.org/en/information/cerebral-palsy-expanded-entry-program-europe.

Dr Joanne Kurtzberg is a part of this program and the Cord Blood Association annual assembly in September 2019, Dr Kurtzberg acknowledged that to this point over 320 children have acquired therapy through this program.

The second EAP for the treament of CP and other neurological diseases with cord blood , was launched 2019 by FamiCord Group, the place NextCell Pharma´s partner Polski Bank Komórek Maciersystych (PBKM) is an important half. The FamiCord-group collaborates with greater than 1300 hospitals around Europe which signifies that patients from all over Europe may have entry to progressive stem cell therapies.

https://www.pbkm.pl/en/about-us/famicord-group-expanded-access-protocol-cord-blood-for-cerebral-palsy

To learn extra about the EAP for the therapy of neurological diseases with cord blood, click on right here:

https://parentsguidecordblood.org/en/news/cerebral-palsy-expanded-access-program-europe

Referenser

1. Arneson, C. L. et al. Prevalence of cerebral palsy: Autism and Developmental Disabilities Monitoring Network, three websites, United States, 2004. Disabil Health J 2, 45-48, doi:10.1016/j.dhjo.2008.08.001 (2009).2. Sun, J. M. & Kurtzberg, J. Stem cell therapies in cerebral palsy and autism spectrum disorder. Dev Med Child Neurol 63, 503-510, doi:10.1111/dmcn.14789 (2021).3. Sun, J. M. & Kurtzberg, J. Cell therapy for numerous central nervous system disorders: inherited metabolic diseases and autism. Pediatr Res 83, 364-371, doi:10.1038/pr.2017.254 (2018).4. Sun, J. et al. Differences in quality between privately and publicly banked umbilical cord blood units: a pilot examine of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion 50, 1980-1987, doi:10.1111/j.1537-2995.2010.02720.x (2010).5. Sun, J. M. et al. Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial. Stem Cells Transl Med 6, 2071-2078, doi:10.1002/sctm.17-0102 (2017).6. Min, K. et al. Umbilical cord blood therapy potentiated with erythropoietin for kids with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells 31, 581-591, doi:10.1002/stem.1304 (2013).7. Kang, M. et al. Involvement of Immune Responses in the Efficacy of Cord Blood Cell Therapy for Cerebral Palsy. Stem Cells Dev 24, 2259-2268, doi:10.1089/scd.2015.0074 (2015).8. Amanat, M. et al. Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial. Stem Cell Res Ther 12, 439, doi:10.1186/s13287-021-02513-four (2021).9. Boruczkowski, D., Pujal, J. M. & Zdolinska-Malinowska, I. Autologous cord blood in kids with cerebral palsy: a overview. Int J Mol Sci 20, doi:10.3390/ijms20102433 (2019).10. Novak, I. et al. Concise Review: Stem Cell Interventions for People With Cerebral Palsy: Systematic Review With Meta-Analysis. Stem Cells Transl Med 5, 1014-1025, doi:10.5966/sctm.2015-0372 (2016).11. Dawson, G. et al. Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial. Stem Cells Transl Med 6, 1332-1339, doi:10.1002/sctm.16-0474 (2017).12. Dawson, G. et al. A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of youngsters with Autism Spectrum Disorder. J Pediatr 222, 164-173 e165, doi:10.1016/j.jpeds.2020.03.011 (2020).